Literature DB >> 24683189

Altered expression of oligodendrocyte and neuronal marker genes predicts the clinical onset of autoimmune encephalomyelitis and indicates the effectiveness of multiple sclerosis-directed therapeutics.

Maria Evangelidou1, Maria Karamita, Sotiris-Spyros Vamvakas, David E Szymkowski, Lesley Probert.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a valuable model for studying immunopathology in multiple sclerosis (MS) and for exploring the interface between autoimmune responses and CNS tissue that ultimately leads to lesion development. In this study, we measured gene expression in mouse spinal cord during myelin oligodendrocyte gp35-55 peptide-induced EAE, using quantitative RT-PCR, to identify gene markers that monitor individual hallmark pathological processes. We defined a small panel of genes whose longitudinal expression patterns provided insight into the timing, interrelationships, and mechanisms of individual disease processes and the efficacy of therapeutics for the treatment of MS. Earliest transcriptional changes were upregulation of Il17a and sharp downregulation of neuronal and oligodendrocyte marker genes preceding clinical disease onset, whereas neuroinflammatory markers progressively increased as symptoms and tissue lesions developed. EAE-induced gene-expression changes were not altered in mice deficient in IKKβ in cells of the myeloid lineage compared with controls, but the administration of a selective inhibitor of soluble TNF to mice from the day of immunization delayed changes in the expression of innate inflammation, myelin, and neuron markers from the presymptomatic phase. Proof of principle that the gene panel shows drug screening potential was obtained using a well-established MS therapeutic, glatiramer acetate. Prophylactic treatment of mice with glatiramer acetate normalized gene marker expression, and this correlated with the level of therapeutic success. These results show that neurons and oligodendrocytes are highly sensitive to CNS-directed autoimmunity before the development of clinical symptoms and immunopathology and reveal a role for soluble TNF in mediating the earliest changes in gene expression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24683189     DOI: 10.4049/jimmunol.1300633

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia.

Authors:  Maria Karamita; Christopher Barnum; Wiebke Möbius; Malú G Tansey; David E Szymkowski; Hans Lassmann; Lesley Probert
Journal:  JCI Insight       Date:  2017-04-20

2.  Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.

Authors:  Christopher J Barnum; Xi Chen; Jaegwon Chung; Jianjun Chang; Martha Williams; Nelly Grigoryan; Raymond J Tesi; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

3.  Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration.

Authors:  Yun Dong; Roman Fischer; Petrus J W Naudé; Olaf Maier; Csaba Nyakas; Maëlle Duffey; Eddy A Van der Zee; Doortje Dekens; Wanda Douwenga; Andreas Herrmann; Eric Guenzi; Roland E Kontermann; Klaus Pfizenmaier; Ulrich L M Eisel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

4.  Sub-region-Specific Optic Nerve Head Glial Activation in Glaucoma.

Authors:  Kazuya Oikawa; James N Ver Hoeve; Leandro B C Teixeira; Kevin C Snyder; Julie A Kiland; N Matthew Ellinwood; Gillian J McLellan
Journal:  Mol Neurobiol       Date:  2020-04-07       Impact factor: 5.590

5.  Bioenergetics of the spinal cord in experimental autoimmune encephalitis of rats.

Authors:  Mariam Al-Shamsi; Allen Shahin; Marwa F Ibrahim; Saeed Tareq; Abdul-Kader Souid; Eric P K Mensah-Brown
Journal:  BMC Neurosci       Date:  2015-06-20       Impact factor: 3.288

6.  The Transcriptome of Type I Murine Astrocytes under Interferon-Gamma Exposure and Remyelination Stimulus.

Authors:  Anna Kudriaeva; Vladimir V Galatenko; Diana V Maltseva; Nadezhda A Khaustova; Ekaterina Kuzina; Alexander G Tonevitsky; Alexander Gabibov; Alexey Belogurov
Journal:  Molecules       Date:  2017-05-15       Impact factor: 4.411

7.  High Speed Ventral Plane Videography as a Convenient Tool to Quantify Motor Deficits during Pre-Clinical Experimental Autoimmune Encephalomyelitis.

Authors:  Jiangshan Zhan; Vladislav Yakimov; Sebastian Rühling; Felix Fischbach; Elena Nikolova; Sarah Joost; Hannes Kaddatz; Theresa Greiner; Julia Frenz; Carsten Holzmann; Markus Kipp
Journal:  Cells       Date:  2019-11-14       Impact factor: 6.600

Review 8.  A New Venue of TNF Targeting.

Authors:  Sophie Steeland; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Int J Mol Sci       Date:  2018-05-11       Impact factor: 5.923

9.  TNFR1 inhibition with a Nanobody protects against EAE development in mice.

Authors:  Sophie Steeland; Sara Van Ryckeghem; Griet Van Imschoot; Riet De Rycke; Wendy Toussaint; Leen Vanhoutte; Christian Vanhove; Filip De Vos; Roosmarijn E Vandenbroucke; Claude Libert
Journal:  Sci Rep       Date:  2017-10-20       Impact factor: 4.379

Review 10.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.